

## Regimen Reference Order – MYEL – lenalidomide maintenance

ARIA: MYEL - [lenalidomide (maint)]

**Planned Course:** Orally daily until disease progression or unacceptable toxicity  
(1 cycle = 28 days)

**Indication for Use:** Multiple Myeloma Maintenance post autologous stem cell transplant

### ***Proceed with treatment if:***

***Day 1 of every cycle & Day 15 of Cycles 1 and 2***

- ***ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $30 \times 10^9/L$***
- ❖ ***Contact prescribing hematologist if parameters not met***

***Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients***

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – MYEL – lenalidomide maintenance

Drug	Dose	CCMB Administration Guideline
lenalidomide	10 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
lenalidomide available dosage strengths: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules		
Classification: Cytotoxic, Hazardous		

## REQUIRED MONITORING

### Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

### Cycles 1 and 2

#### Day 1

- CBC, serum creatinine, electrolytes, calcium, albumin, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

#### Day 15

- CBC as per Physician Orders

### Cycle 3 and Onwards

#### Day 1

- CBC, serum creatinine, electrolytes, calcium, albumin, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Per RevAid Program or Reddy2Assist Program – See Additional Information

- Patients of childbearing potential require  $\beta$ HCG according to RevAid/Reddy2Assist Program requirements

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
None required		

## INSTRUCTIONS FOR PATIENT

- Reinforce applicable safe handling precautions of medications, blood and body fluids while on lenalidomide

## ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- lenalidomide starts 3 to 4 months post autologous stem cell transplant
- lenalidomide is teratogenic
- Patients of childbearing potential will require monthly pregnancy tests ( $\beta$ HCG) that must be done within 7 days of the next prescription fill
- Effective November 25<sup>th</sup>, 2021, all new patients starting on lenalidomide will be enrolled in Reddy2Assist Program. lenalidomide can only be given to patients who are registered and meet all conditions of Reddy2Assist Program
- Existing patients on lenalidomide (started prior to November 25<sup>th</sup>, 2021) are currently enrolled in RevAid Program and must meet all conditions of RevAid Program
- lenalidomide will be dispensed by CCMB Pharmacy